A systematic review and meta-analysis of stereotactic body radiation therapy for colorectal pulmonary metastases Journal Article


Authors: Cao, C.; Wang, D.; Tian, D. H.; Wilson-Smith, A.; Huang, J.; Rimner, A.
Article Title: A systematic review and meta-analysis of stereotactic body radiation therapy for colorectal pulmonary metastases
Abstract: Background: There is growing evidence to support the hypothesis that radical treatment of pulmonary oligometastatic disease with stereotactic body radiation therapy (SBRT) can improve oncological outcomes. However, some reports suggest colorectal cancer (CRC) pulmonary metastases are associated with radioresistance. The present systematic review aimed to assess the local control (LC), overall survival (OS), and progression-free survival (PFS) of patients with CRC pulmonary metastases treated by SBRT. Secondary outcomes included assessment of peri-procedural complications and identification of prognostic factors on LC. Methods: Electronic databases were systematically searched from their dates of inception using predefined criteria. Summative statistical analysis was performed for patients with CRC pulmonary metastases, and comparative meta-analysis was performed for patients with CRC versus non-CRC pulmonary metastases. Results: Using predefined criteria, 18 relevant studies were identified from the existing literature. LC for CRC pulmonary metastases treated by SBRT at 1-, 2-, and 3-year were estimated to be 81%, 66%, and 60%, respectively. OS and PFS at 3-year were 52% and 13%, respectively. Patients with CRC pulmonary metastases were associated with significantly lower LC compared to non-CRC pulmonary metastases [HR, 2.93; 95% confidence interval (CI), 1.93-4.45; P<0.00001], but higher OS (HR, 0.61; 95% CI, 0.45-0.82; P=0.001). There were no reported periprocedural mortalities and low incidences of periprocedural morbidities. Conclusions: These findings may have implications for patient and treatment selection, dose fractionation, and support the hypothesis that CRC pulmonary metastases may require higher biological effective doses while respecting normal tissue constraints when treated with SBRT. © 2019 Journal of Thoracic Disease. All rights reserved.
Keywords: cancer survival; overall survival; colorectal cancer; progression free survival; incidence; morbidity; lung metastasis; systematic review; radiation dose fractionation; cancer control; stereotactic body radiation therapy; meta-analysis; clinical outcome; pulmonary metastasis; cancer prognosis; human; article; stereotactic body radiation therapy (sbrt); colorectal cancer (crc)
Journal Title: Journal of Thoracic Disease
Volume: 11
Issue: 12
ISSN: 2072-1439
Publisher: Pioneer Bioscience Publishing Company  
Date Published: 2019-12-01
Start Page: 5187
End Page: 5198
Language: English
DOI: 10.21037/jtd.2019.12.12
PROVIDER: scopus
PMCID: PMC6988072
PUBMED: 32030236
DOI/URL:
Notes: Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. James Huang
    214 Huang
  2. Andreas Rimner
    525 Rimner
  3. Christopher Qian Cao
    9 Cao